Biomedical research tools: Bayesian perspective (I)

Medicina Clinica

Volumn 119, Issue 7, 2002, Pages 265-268

  Álamo Santana, Fayna ^a   VÁzquez Polo, Francisco José ^a   Rodríguez Pérez, José Carlos ^a  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BAYES THEOREM; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; HUMAN; MALE; MEDICAL RESEARCH; MONTE CARLO METHOD; REVIEW; STATISTICAL MODEL; CLINICAL TRIAL;

BAYES THEOREM; CLINICAL TRIALS;

EID: 0037037268     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(02)73381-2     Document Type: Review

References (20)

1. Silva Ayçaguer LC, Muñoz Villegas A. Debate sobre métodos frecuentistas versus bayesianos. Gac Sanitaria 2000;14:482-94.
2. Bacallao J. La perspectiva exploratorio-confirmatoria en las aplicaciones biomédicas de la estadística: dos diÁlogos (I). Bayesianismo frente al frecuentalismo: sus respectivas implicaciones prÁcticas en relación con el anÁlisis de datos. Med Clin (Barc) 1996;107:467-71. anÁlisis de datos
3. Bacallao J. La perspectiva exploratorio-confirmatoria en las aplicaciones biomédicas de la estadística: dos diÁlogos (y II). Consideraciones criticas acerca de las pruebas de significacíon. Med Clin (Barc) 1996;107:539-43.
4. Lilford RJ, Braunholtz D. For debate: the statistical basis of public policy: a paradigm shift is overdue. BMJ 1996;313:603-7.
5. Bland JM, Altman DG. Bayesians and frequentists. Br Med J 1998;317: 1151.
6. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. An introduction to bayesian methods in health technology assessment. BMJ 1999; 319:508-12.
7. Matchar DB, Simel DL, Geweke JF, Feussner JR. A Bayesian method for evaluating medical test operating characteristics when some patients' conditions fail to be diagnosed by the reference standard. Med Decis Making 1990;10:102-12.
8. Claxton K, Neuman PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 2001;17:38-55.
9. Lee SJ, Zelen M. Clinical trials and sample size considerations: another perspective. Statistical Science 2000;15:95-110.
10. O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis for clinical trial data. Health Economics 2001;10:313-5.
11. Luce BR, Shin YC, Claxton K. Introduction. Bayesian approaches to technology assessment and decision making. Int J Technol Assess Health Care 2001;17:1-5.
12. Sterne JAC, Smith GD. Sifting the evidence-what's wrong with significance tests? BMJ 2001;322:226-31.
13. Freedman L. Bayesian statistical methods. BMJ 1996;313:569-70.
14. Kadane BJ. Prime time for Bayes. Controled Clinical Trials 1995;16:313-8.
15. Bayes T. Essay towards solving a problem in the doctrine of chances. Philosophical Transactions. London: Royal Society 1763;53:370-718. [Reprinted in Biometrika 1958;45:293-3151.
16. Lindley DV. Introduction to probability and statistics from a bayesian viewpoint. Cambridge: Cambridge University Press, 1965.
17. Pozo Rodríguez F. La eficacia de las pruebas diagnósticas (y II). Med Clin (Barc) 1988;91:177-83.
18. Claxton K, Thompson KM. A dynamic programming approach to the efficient desig of clinical trials. J Health Economic 2001;20:797-822.
19. Davidoff F. Standing statistics right side up. Ann Intern Med 1999;130: 1019-21.
20. Rodríguez-Pérez JC, Rodríguez-Esparragón F, HernÁndez-Perera O, Anabitarte A, Losada A, Medina A, et al. Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene. J Am Coll Cardiol, 2001;37:1536-42